$AHCONeutralLow

Schuster III Russell E. sold $113K of AHCO

Schuster III Russell E. (Chief Commercial Officer) sold 11,275 shares of AdaptHealth Corp. (AHCO) at $10.06 ($0.11M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

6/10
3/10
Low
Neutral
After-hours/filing update on 2026-06-03 for a 2026-06-01 sale
Neutral; insider selling can be read negatively, but 10b5-1 reduces interpretive weight

This is an insider Form 4 sale disclosure; it may slightly affect sentiment but does not introduce new company fundamentals.

AdaptHealth CCO Russell E. Schuster III sold $113,426 of AHCO shares via an open-market transaction under a 10b5-1 plan.

Low likelihood of a sustained price move; any reaction is likely muted given the disclosed 10b5-1 plan.

Background

The article is an SEC Form 4 insider transaction (officer sale) for AdaptHealth, reported via EDGAR.

Why it matters

Focus is on whether the sale is scheduled (10b5-1) and whether it meaningfully changes the risk/reward for AHCO holders; no new business developments are provided.

Market relevance

A scheduled insider sale is disclosed; traders may monitor for follow-on insider buying/selling patterns, but this filing alone is unlikely to drive a major repricing.

Market effects

Minimal; single-company insider sale with no sector-wide catalyst.

None indicated.

None indicated.

Alternative perspectives

A 10b5-1 sale can still coincide with internal expectations of near-term liquidity needs, but it is not strong evidence of deteriorating fundamentals.

Insider sales often reflect diversification or scheduled selling; without changes in buying activity or new disclosures, signal strength is limited.

Key entities

  • AdaptHealth Corp.

    Subject of the SEC Form 4 insider sale disclosure.

  • Schuster III Russell E.

    Chief Commercial Officer who executed the open-market sale under a 10b5-1 plan.

Related articles

$AHCOMed

Why AdaptHealth (AHCO) Shares Are Sliding Today

AdaptHealth (AHCO) shares fell 8.5% after the company reported disappointing Q1 2026 results, including a significant earnings miss and worsening profitability despite a revenue beat. The GAAP loss per share was $0.12, far worse than analyst estimates. Although revenue increased by 5.4% to $819.8 million, the operating margin contracted sharply, and the company experienced increased cash burn, leading to investor concerns about rising costs and operational efficiency.

$AHCOMed

Is It Time To Reassess AdaptHealth (AHCO) After A 60% One Year Rally?

AdaptHealth (AHCO) has seen a significant 60% rally over the past year, prompting a reassessment of its current valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 64.0%, while its P/S ratio indicates a modest discount compared to a proprietary fair ratio. The article also presents bullish and bearish narratives, with fair values ranging from US$9.50 to US$17.00 per share, offering investors different perspectives on the company's future.

$AHCOMed

Vanguard Group Inc. Has $100.93 Million Stock Holdings in AdaptHealth Corp. $AHCO

Vanguard Group Inc. has scaled back its stake in AdaptHealth Corp. by 4.9% in the third quarter, now holding 11.28 million shares valued at approximately $100.93 million. This comes as AdaptHealth reported a significant earnings miss despite exceeding revenue estimates, leading to a negative net margin. The company currently has a "Moderate Buy" consensus rating from analysts, with institutional ownership remaining high at 82.67%.

$AHCOMed

Segall Bryant & Hamill LLC Cuts Stock Position in AdaptHealth Corp. $AHCO

Segall Bryant & Hamill LLC significantly reduced its stake in AdaptHealth Corp. ($AHCO) by 8.2% in the third quarter, now owning 3.18% of the company's stock valued at $38.48 million. Other institutional investors showed mixed activity, with some increasing and others initiating positions. AdaptHealth reported disappointing Q3 earnings, missing consensus estimates, and analysts have issued varied ratings, with a consensus price target of $13.25.

$AHCOMed

How a US$1 Billion Exclusive Contract At AdaptHealth (AHCO) Has Changed Its Investment Story

AdaptHealth (AHCO) has secured a five-year, US$1 billion exclusive contract to provide home medical equipment and supplies to a large national healthcare system. This agreement is expected to generate at least US$200 million in annual revenue, strengthening the company's financial position and profitability. While this contract addresses previous concerns about trimmed guidance and supports AdaptHealth's investment narrative, execution risk remains a factor, especially given uncovered interest expenses.